Bio-Techne 향후 성장

Future 기준 점검 3/6

Bio-Techne (는) 각각 연간 23.6% 및 6.4% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 23.8% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 15.2% 로 예상됩니다.

핵심 정보

23.6%

이익 성장률

23.82%

EPS 성장률

Life Sciences 이익 성장	17.6%
매출 성장률	6.4%
향후 자기자본이익률	15.17%
애널리스트 커버리지	Good
마지막 업데이트	08 Nov 2025

최근 향후 성장 업데이트

Bio-Techne Corporation (NASDAQ:TECH) Just Released Its First-Quarter Earnings: Here's What Analysts Think

Nov 08

Recent updates

Bio-Techne Corporation (NASDAQ:TECH) Just Released Its First-Quarter Earnings: Here's What Analysts Think

Nov 08

Bio-Techne: Attractive Markets And A Good Moat, But Valuation Is Seldom A Bargain

Feb 27

Here's Why Bio-Techne (NASDAQ:TECH) Can Manage Its Debt Responsibly

Jan 21

At US$71.48, Is Bio-Techne Corporation (NASDAQ:TECH) Worth Looking At Closely?

Jan 03

Why We're Not Concerned About Bio-Techne Corporation's (NASDAQ:TECH) Share Price

Dec 15

Innovations In Molecular Diagnostics And Decisive Focus On Growth Verticals Promise Revenue Surge Amid Challenges

Aug 22 Bio-Techne's investment in advanced diagnostics and specialized instruments like Leo suggests strong potential for revenue growth from increased sales and market adoption.

Bio-Techne: Secular Growth Opportunities Always Exhibit Financial Excellence

Apr 04

이익 및 매출 성장 예측

NasdaqGS:TECH - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)
날짜	매출	이익	자유현금흐름	영업현금흐름	평균 애널리스트 수
6/30/2028	1,440	268	N/A	464	8
6/30/2027	1,309	235	397	451	13
6/30/2026	1,224	202	268	274	14
9/30/2025	1,217	78	224	251	N/A
6/30/2025	1,220	73	257	288	N/A
3/31/2025	1,209	132	221	265	N/A
12/31/2024	1,196	158	254	305	N/A
9/30/2024	1,172	151	245	303	N/A
6/30/2024	1,159	168	236	299	N/A
3/31/2024	1,154	203	251	307	N/A
12/31/2023	1,145	224	225	276	N/A
9/30/2023	1,144	247	215	258	N/A
6/30/2023	1,137	285	216	254	N/A
3/31/2023	1,124	271	233	274	N/A
12/31/2022	1,120	262	252	296	N/A
9/30/2022	1,118	292	285	333	N/A
6/30/2022	1,106	272	280	325	N/A
3/31/2022	1,076	225	302	345	N/A
12/31/2021	1,030	210	308	346	N/A
9/30/2021	985	177	295	335	N/A
6/30/2021	931	140	308	352	N/A
3/31/2021	848	184	225	275	N/A
12/31/2020	799	175	201	250	N/A
9/30/2020	760	248	179	231	N/A
6/30/2020	739	229	153	205	N/A
3/31/2020	755	187	170	216	N/A
12/31/2019	745	195	165	207	N/A
9/30/2019	734	93	151	183	N/A
6/30/2019	714	96	N/A	182	N/A
3/31/2019	703	121	N/A	191	N/A
12/31/2018	682	96	N/A	173	N/A
9/30/2018	661	128	N/A	165	N/A
6/30/2018	643	126	N/A	170	N/A
3/31/2018	619	112	N/A	156	N/A
12/31/2017	599	114	N/A	160	N/A
9/30/2017	577	73	N/A	162	N/A
6/30/2017	563	76	N/A	144	N/A
3/31/2017	541	74	N/A	129	N/A
12/31/2016	528	82	N/A	141	N/A
9/30/2016	517	101	N/A	138	N/A
6/30/2016	499	104	N/A	144	N/A
3/31/2016	482	105	N/A	145	N/A
12/31/2015	465	99	N/A	138	N/A
9/30/2015	456	107	N/A	135	N/A
6/30/2015	452	108	N/A	139	N/A
3/31/2015	427	108	N/A	140	N/A
12/31/2014	408	116	N/A	144	N/A

애널리스트 향후 성장 전망

수입 대 저축률: TECH 의 연간 예상 수익 증가율(23.6%)이 saving rate(3.3%)보다 높습니다.

수익 vs 시장: TECH 의 연간 수익(23.6%)이 US 시장(16.1%)보다 빠르게 성장할 것으로 예상됩니다.

고성장 수익: TECH 의 수입은 향후 3년 동안 상당히 증가할 것으로 예상됩니다.

수익 대 시장: TECH 의 수익(연간 6.4%)이 US 시장(연간 10.5%)보다 느리게 성장할 것으로 예상됩니다.

고성장 매출: TECH 의 수익(연간 6.4%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: TECH의 자본 수익률은 3년 후 15.2%로 낮을 것으로 예상됩니다.

성장 기업 찾아보기

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2025/12/01 08:26
종가	2025/11/28 00:00
수익	2025/09/30
연간 수익	2025/06/30

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 Github 페이지에서 확인할 수 있으며, 보고서 활용 방법에 대한 가이드와 Youtube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Bio-Techne Corporation는 25명의 분석가가 다루고 있습니다. 이 중 14명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
David Toung	Argus Research Company
Catherine Ramsey Schulte	Baird
Robert Wasserman	Benchmark Company

Bio-Techne 향후 성장

Future 기준 점검 3/6

핵심 정보

최근 향후 성장 업데이트

Bio-Techne Corporation (NASDAQ:TECH) Just Released Its First-Quarter Earnings: Here's What Analysts Think

Consensus EPS estimates fall by 13%

Price target decreased by 11% to US$71.28

Consensus EPS estimates fall by 14%

Consensus EPS estimates fall by 17%

Price target decreased by 19% to US$81.33

Recent updates

Bio-Techne Corporation (NASDAQ:TECH) Just Released Its First-Quarter Earnings: Here's What Analysts Think

First quarter dividend of US$0.08 announced

First quarter 2026 earnings: EPS and revenues miss analyst expectations

Bio-Techne Corporation Declares Dividend for the Quarter Ended September 30, 2025, Payable on November 28, 2025

Bio-Techne Corporation and Nucleai Announces the Presentation of Pivotal Data from the SECOMBIT Clinical Trial at the Society for Immunotherapy of Cancer 2025 Annual Meeting

Bio-Techne Launches ProximityScope Assay on the Bond Rx Platform from Leica Biosystems to Advance Spatial Protein-Protein Interactions Research

Bio-Techne Corporation to Report Q1, 2026 Results on Nov 05, 2025

Bio-Techne Advances Spatial Biology Solutions Bridging Translational Research to Clinical Applications

Bio-Techne Corporation, Annual General Meeting, Oct 30, 2025

Independent Director notifies of intention to sell stock

Fourth quarter dividend of US$0.08 announced

Full year 2025 earnings: EPS misses analyst expectations

Bio-Techne Corporation Declares Dividend for the Quarter Ended June 30, 2025, Payable on August 29, 2025

Bio-Techne: Coveted Life Sciences Asset On Sale Due To Academic Pressures

Executive VP of Finance & CFO exercised options and sold US$2.1m worth of stock

Investors Still Waiting For A Pull Back In Bio-Techne Corporation (NASDAQ:TECH)

Investor sentiment improves as stock rises 17%

What Does Bio-Techne Corporation's (NASDAQ:TECH) Share Price Indicate?

Consensus EPS estimates fall by 13%

Bio-Techne Corporation to Showcase Next-Generation Solutions for Gene and Cell Therapy At American Society of Gene & Cell Therapy 2025

Third quarter dividend of US$0.08 announced

Price target decreased by 11% to US$71.28

New minor risk - Earnings quality

Third quarter 2025 earnings: EPS misses analyst expectations

Bio-Techne Corporation (NasdaqGS:TECH) announces an Equity Buyback for $500 million worth of its shares.

Is Bio-Techne (NASDAQ:TECH) Using Too Much Debt?

Bio-Techne Announces Early Access Program for Next-Generation Spatial Protein Proximity Detection

Bio-Techne Corporation to Report Q3, 2025 Results on May 07, 2025

Market Participants Recognise Bio-Techne Corporation's (NASDAQ:TECH) Earnings

Bio-Techne Corporation Begins Shipping Leo - A Next Generation High-Throughput Simple Western System

Bio-Techne Launches New Panel Resolving Hard-To-Decipher Carrier Screening Genes

Bio-Techne: Attractive Markets And A Good Moat, But Valuation Is Seldom A Bargain

Bio-Techne Corporation Launches Expanded Menu of RNAscope Probes for Human and Mouse Transcriptome to Advance Spatial Biology

Bio-Techne Corporation Announces Release of GMP TcBuster Non-Viral Genome Engineering System

Second quarter dividend of US$0.08 announced

Second quarter 2025 earnings: EPS and revenues exceed analyst expectations

Bio-Techne Corporation Declares Dividend for the Quarter Ended December 31, 2024, Payable on February 28, 2025

Bio-Techne Appoints Amy E. Herr to Board of Directors

CEO, President & Director notifies of intention to sell stock

Here's Why Bio-Techne (NASDAQ:TECH) Can Manage Its Debt Responsibly

Bio-Techne Expands R&D Systems Ai-Engineered Designer Protein Portfolio to Advance Cell Therapy and Regenerative Medicine

At US$71.48, Is Bio-Techne Corporation (NASDAQ:TECH) Worth Looking At Closely?

Why We're Not Concerned About Bio-Techne Corporation's (NASDAQ:TECH) Share Price

Bio-Techne Corporation to Highlight Novel Solutions for Cancer and Carrier Screening At Amp 2024 Annual Meeting & Expo

New minor risk - Earnings quality

Bio-Techne Corporation to Present at the Society for Immunotherapy of Cancer (SITC) 39Th Annual Meeting

Bio-Techne Corporation Announces the Release of Clinically Relevant Spatial Biology Data

First quarter dividend of US$0.08 announced

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Bio-Techne Corporation Declares Dividend for the Quarter Ended September 30, 2024, Payable on November 22, 2024

ScaleReady and Bio-Techne Corporation Announce Optimal Closed System Cytokine Packaged for Single Step Use in Closed System G-Rex® Manufacture of CAR-T and TCR Therapies

Bio-Techne Corporation, Annual General Meeting, Oct 24, 2024

Full year 2024 earnings: EPS misses analyst expectations

Innovations In Molecular Diagnostics And Decisive Focus On Growth Verticals Promise Revenue Surge Amid Challenges

Consensus EPS estimates fall by 14%

Fourth quarter dividend of US$0.08 announced

Full year 2024 earnings: EPS misses analyst expectations

Executive VP of Finance & CFO exercised options and sold US$1.8m worth of stock

Bio-Techne Corporation Declares Dividend for the Quarter Ended June 30, 2024, Payable on August 30, 2024

Bio-Techne Corporation Announces the Launch of the Leo™ System

Executive VP of Finance & CFO exercised options and sold US$1.1m worth of stock

Bio-Techne Corporation to Showcase Multiple Applications of the MauriceFlex™? System at the Annual ASMS Conference

Bio-Techne Corporation and Regulus Therapeutics Inc. Announces Continued Technical and Clinical Collaboration

Third quarter dividend of US$0.08 announced

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Bio-Techne Corporation Declares Dividend for the Quarter Ended March 31, 2024, Payable on May 24, 2024

Bio-Techne Corporation Appoints Dr. Judith Klimovsky to Board of Directors

Bio-Techne Corporation and Novomol-Dx Announce Point-of-Care Ocular Biomarker Assay

Bio-Techne: Secular Growth Opportunities Always Exhibit Financial Excellence